Abstract
The article is devoted to the study of regulatory approaches to the sphere of real-world data (RWD) and real world evidence (RWE) in the countries of the Asia-Pacific Region (China, South Korea, Japan, Taiwan, etc.) and examples of their practical application for health technology assessment. The peculiarities of collecting and gaining access to RWD/RWE in Asian countries, prerequisites for the development of this direction, adopted regulations, developed methodological guidelines, promising areas of application, and clinical and economic research based on country-specific data are considered. The existing practices in Asian countries represent valuable experience, some of which could be considered for implementation in the national practice.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
